Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 4

DRAGON PHARMACEUTICAL INC

Form 4 October 04, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer

subject to Section 16. Form 4 or

Form 5 obligations

may continue. See Instruction STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

DRAGON PHARMACEUTICAL

(Print or Type Responses)

1(b).

(Last)

1. Name and Address of Reporting Person *

WICK ALEXANDER

(First) (Middle)

C/O DRAGON PHARMACEUTICAL INC, 1056 WEST HASTINGS, SUITE 1900

(Street) 4. If Amendment, Date Original

Symbol

INC [DRUG]

(Month/Day/Year)

09/30/2005

Filed(Month/Day/Year)

3. Date of Earliest Transaction

Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

VANCOUVER BRITISH COLUMBIA, A1 V6E 2E9

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

(City)

(Month/Day/Year) Execution Date, if

(State)

2. Transaction Date 2A. Deemed (Month/Day/Year)

TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported

Transaction(s)

Person

Issuer

below)

_X__ Director

X_ Officer (give title

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial Ownership (Instr. 4) (Instr. 4)

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

5. Relationship of Reporting Person(s) to

(Check all applicable)

President

6. Individual or Joint/Group Filing(Check

below)

10% Owner

Other (specify

Estimated average

burden hours per

(Instr. 3 and 4) Code V Amount (D) Price

(A)

or

4. Securities

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 4

4.

Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionDerivative		Expiration Date		Underlying Securities		
Security	or Exercise		any	Code	Securities		(Month/Day/Y	ear)	(Instr. 3 and	4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A	or (
	Derivative				Disposed of	(D)				
	Security				(Instr. 3, 4, and					
					5)					
							Date Exercisable	Expiration Date	Title	Amount of Number of
				Code V	(A)	(D)	Excicisation	Date		Shares
Options	\$ 0.74	09/30/2005		A	400,000		09/30/2005	09/30/2010	Common	400,00

5. Number of

6. Date Exercisable and

7. Title and Amount of

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
WICK ALEXANDER						
C/O DRAGON PHARMACEUTICAL INC			Descident			
1056 WEST HASTINGS, SUITE 1900	X		President			
VANCOUVER BRITISH COLUMBIA, A1 V6E 2E9						

Signatures

1. Title of 2.

/s/ Alexander Wick by Maggie Deng POA

10/01/2005

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

3. Transaction Date 3A. Deemed

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2